BioCryst Pharmaceuticals, Inc. | Company Profile
Company Directory for BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc.
Overview
BioCryst Pharmaceuticals, Inc. is a global biotechnology company based in Durham, North Carolina. Founded in 1986 as a spin-off from the University of Alabama at Birmingham, it is one of the oldest independent biotechnology firms. The company specializes in drug discovery, development, and commercialization, focusing on oral small-molecule and protein therapeutics. Its primary therapeutic areas include hereditary angioedema and other rare diseases.
The organization has developed several prescription drug treatments, including Orladeyo for hereditary angioedema, Peramivir for influenza, Fodosine for T-cell leukemia, Ulodesine for autoimmune diseases and Hepatitis C, and Avoralstat for vision loss related to diabetes. BioCryst operates a 35,000 square-foot research center in Riverchase Corporate Park. Strategic partnerships include collaborations with Torii Pharmaceutical and Johnson & Johnson for drug development.
Basic Information
| Industry | Research |
|---|---|
| Founded | 1986 |
| Revenue | $450.7M |
| Headquarters | 4505 Emperor Blvd., Suite 200, Durham, NC 27703, United States |
| Languages | English |
| Alexa Ranking |
Contact Details
- Phone: +1 919-859-1302
- Website: biocryst.com
- LinkedIn: linkedin.com/company/biocryst-pharmaceuticals
Key Focus Areas & Initiatives
- Drug discovery
- Clinical development
- Rare diseases
- Regulatory affairs
- Product commercialization
- Biotechnology
- Life sciences
- Health care
- Biotechnology research
- C1 esterase inhibitor
- Cryogenic electron microscopy
- Small molecule drugs
- Biopharmaceutical development
- Targeted therapy
- Crystallography
- Enzyme inhibitors
- Drug discovery platform
- Structure-guided drug design
- Biotech innovation
- Medicinal chemistry
- Molecular modeling
- Biologics
- Oral small-molecule therapeutics
- Protein therapeutics
- Complement system targeting
- Advanced technologies
- Netherton syndrome
- Next-generation oral inhibitors
- Molecular docking
- Structure-based design
- Virtual screening
- Molecular dynamics simulations
- Plasma kallikrein inhibitors
- Hereditary angioedema
- Complement-mediated diseases
- Investigator-initiated studies
- Protein chemistry
- Molecular diagnostics
- Diabetic macular edema
- Orphan drugs
- Clinical trials
- Rare disease treatments
- Rare disease therapeutics
- Pharmaceuticals
- Healthcare
- KLK5 inhibitors
- Biopharmaceuticals
- Drug development
- Novel therapies
- Patient advocacy
- Compassionate use programs
- Expanded access programs
- Medical information
- Research partnerships
- FDA approvals
- Pediatric patients
- Targeted therapies
- Innovative medicines
- Patient-centric approach
- Healthcare professionals
- Scientific research
- Collaborative research
- Patient outcomes
- Community engagement
- Regulatory compliance
- Global markets
- Phase clinical trials
- Real-world effectiveness
- Patient-reported outcomes
- Breakthrough therapies
- Translational research
- Unmet medical needs
- Pharmaceutical collaborations
- Clinical research integrity
- Evolution of drug design
- Healthcare accessibility
- Charitable contributions
- Medical education grants
- Research and development
- Patient privacy assurance
- Advocacy organizations
- Transformative treatments
- Manufacturing
- Health, wellness & fitness
- Hospital & health care
- Medical
- Research & development
- Mechanical or industrial engineering
Technologies Used
- Mimecast
- Remote
- SendInBlue
- WP Engine